Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

238,877 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immunosenescence: molecular mechanisms and diseases.
Liu Z, Liang Q, Ren Y, Guo C, Ge X, Wang L, Cheng Q, Luo P, Zhang Y, Han X. Liu Z, et al. Among authors: zhang y. Signal Transduct Target Ther. 2023 May 13;8(1):200. doi: 10.1038/s41392-023-01451-2. Signal Transduct Target Ther. 2023. PMID: 37179335 Free PMC article. Review.
COVID-19: immunopathogenesis and Immunotherapeutics.
Yang L, Liu S, Liu J, Zhang Z, Wan X, Huang B, Chen Y, Zhang Y. Yang L, et al. Among authors: zhang z, zhang y. Signal Transduct Target Ther. 2020 Jul 25;5(1):128. doi: 10.1038/s41392-020-00243-2. Signal Transduct Target Ther. 2020. PMID: 32712629 Free PMC article. Review.
Immune characteristics of severe and critical COVID-19 patients.
Yang L, Gou J, Gao J, Huang L, Zhu Z, Ji S, Liu H, Xing L, Yao M, Zhang Y. Yang L, et al. Among authors: zhang y. Signal Transduct Target Ther. 2020 Aug 31;5(1):179. doi: 10.1038/s41392-020-00296-3. Signal Transduct Target Ther. 2020. PMID: 32868756 Free PMC article. No abstract available.
An individualized immune signature of pretreatment biopsies predicts pathological complete response to neoadjuvant chemoradiotherapy and outcomes in patients with esophageal squamous cell carcinoma.
Zhang C, Zhang G, Sun N, Zhang Z, Xue L, Zhang Z, Yang H, Luo Y, Zheng X, Zhang Y, Yuan Y, Lei R, Yang Z, Zheng B, Wang L, Che Y, Wang F, Wang S, Gao S, Xue Q, Zhang Y, He J. Zhang C, et al. Among authors: zhang g, zhang z, zhang y. Signal Transduct Target Ther. 2020 Sep 4;5(1):182. doi: 10.1038/s41392-020-00221-8. Signal Transduct Target Ther. 2020. PMID: 32883946 Free PMC article.
Immunosenescence: a key player in cancer development.
Lian J, Yue Y, Yu W, Zhang Y. Lian J, et al. Among authors: zhang y. J Hematol Oncol. 2020 Nov 10;13(1):151. doi: 10.1186/s13045-020-00986-z. J Hematol Oncol. 2020. PMID: 33168037 Free PMC article. Review.
Myeloid cells in COVID-19 microenvironment.
Qin G, Liu S, Yang L, Yu W, Zhang Y. Qin G, et al. Among authors: zhang y. Signal Transduct Target Ther. 2021 Oct 27;6(1):372. doi: 10.1038/s41392-021-00792-0. Signal Transduct Target Ther. 2021. PMID: 34707085 Free PMC article. Review.
XELOX (capecitabine plus oxaliplatin) plus bevacizumab (anti-VEGF-A antibody) with or without adoptive cell immunotherapy in the treatment of patients with previously untreated metastatic colorectal cancer: a multicenter, open-label, randomized, controlled, phase 3 trial.
Pan QZ, Zhao JJ, Liu L, Zhang DS, Wang LP, Hu WW, Weng DS, Xu X, Li YZ, Tang Y, Zhang WH, Li JY, Zheng X, Wang QJ, Li YQ, Xiang T, Zhou L, Yang SN, Wu C, Huang RX, He J, Du WJ, Chen LJ, Wu YN, Xu B, Shen Q, Zhang Y, Jiang JT, Ren XB, Xia JC. Pan QZ, et al. Among authors: zhang ds, zhang wh, zhang y. Signal Transduct Target Ther. 2024 Apr 3;9(1):79. doi: 10.1038/s41392-024-01788-2. Signal Transduct Target Ther. 2024. PMID: 38565886 Free PMC article. Clinical Trial.
238,877 results
You have reached the last available page of results. Please see the User Guide for more information.